Insider Selling: BioAge Labs (NASDAQ:BIOA) Insider Sells 18,000 Shares of Stock

BioAge Labs, Inc. (NASDAQ:BIOA) insider Paul Rubin sold 18,000 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total value of $216,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

BioAge Labs Stock Up 0.6%

BIOA stock traded up $0.07 on Thursday, reaching $12.75. 1,932,533 shares of the company were exchanged, compared to its average volume of 287,846. The stock has a market capitalization of $457.09 million, a price-to-earnings ratio of -8.39 and a beta of 1.74. BioAge Labs, Inc. has a 12 month low of $2.88 and a 12 month high of $13.10. The company has a fifty day simple moving average of $7.73.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.

Analyst Ratings Changes

A number of research firms recently weighed in on BIOA. Citigroup lifted their target price on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new stake in BioAge Labs during the second quarter valued at approximately $57,000. Geode Capital Management LLC lifted its position in shares of BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in BioAge Labs in the second quarter valued at $27,000. Intech Investment Management LLC acquired a new position in BioAge Labs during the second quarter worth $60,000. Finally, Jefferies Financial Group Inc. acquired a new position in BioAge Labs during the second quarter worth $206,000.

About BioAge Labs

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.